Dr. Brady Wu is a multidisciplinary scientist and biotech leader. He holds a Ph.D. in Chemistry from The Ohio State University (2007–2013), where he pioneered solid-state NMR studies of amyloid fibril dynamics, and a Peking University honors B.S. in Biology (2003–2007). At GenScript (2013–2021), he led 100+ teams in recombinant protein production service and global project management. As the Founding CEO of Solvo Biotherapeutics (2022–2024), he built China’s top cell-free protein synthesis platform with a 15+ team. Now leading the Protein Science group at Biointron (2024–present), he drives ADC conjugation, developability assessment, and recombinant protein/antibody R&D efforts in the company.